Heather Berger, Ph.D., currently serves as a principal at SR One, concentrating on early-stage innovative therapeutic opportunities. Dr. Berger is currently a board member of Second Genome and Entasis Therapeutics (ETTX). Prior to SR One, she was with Sofinnova Investments, and prior to that, was an equity research analyst at Wedbush Securities and an associate at JMP Securities, focused primarily on therapies for rare disease. Dr. Berger was formerly a chemist at the Astellas Research Institute and adjunct faculty at the Feinberg Northwestern School of Medicine. Dr. Berger received her Ph.D. in chemistry at Northwestern University, MSc. in organic chemistry at the Weizmann Institute of Science and her B.S. from Tufts University.